Malú Gámez Tansey

Malú Gámez Tansey,

Norman And Susan Fixel Professor Of Neuroscience And Neurology, Director, Parkinson’s Foundation Research Center Of Excellence At UF

Department: Department of Neuroscience
Business Phone: (352) 294-4096
Business Email: mgtansey@ufl.edu

About Malú Gámez Tansey

Maria de Lourdes (Malú) was born in El Paso, Texas and attended Loretto Academy high school. Dr. Tansey obtained her B.S/M.S in Biological Sciences from Stanford University and her Ph.D. in Cell Regulation from UT Southwestern in Dallas, TX followed by post-doctoral work in neuroscience at Washington University Medical School. Prior to setting up her academic research lab in 2002 at UT Southwestern Medical Center in the Department of Physiology, she was head of the Chemical Genetics group at Xencor, a biotechnology company in Monrovia, working on novel TNF inhibitors that she used as tools in academia to investigate the role of neuroinflammation in neurodegenerative disease and which have now advanced to clinical trials in Alzheimer’s disease and COVID19 for cytokine storm.

After becoming a tenured Associate Professor of Physiology at UT Southwestern in 2008, Dr. Tansey was recruited to Emory University in Atlanta, GA by the Department of Physiology where she became a member of the Center for Neurodegenerative Disease (CND) and also served as Senior Director of Graduate Studies (DGS) for the Emory Neuroscience Graduate Program and a member of the Executive Committee of the Emory Immunology and Molecular Pathogenesis (IMP) Graduate Program. While at Emory, she catalyzed multiple initiatives to expand and coalesce neuroinflammation efforts across the medical school and helped establish the Center for Neurodysfunction and Inflammation (CNI) at Emory in 2018. In 2019, she was recruited to the University of Florida to be Director of the Center for Translational Research in Neurodegenerative Disease (CTRND) and the first endowed Norman and Susan Fixel Chair in Neuroscience and Neurology at the University of Florida.

Today, Tansey’s lab employs multi-disciplinary approaches to investigate the role of inflammation and immune system responses in brain health and the development of neurodegenerative diseases with particular focus on the gut-brain axis . Her long-term goal is to train the next generation of scientists who can/and to develop better therapies to prevent and/or delay these disorders.

As a Hispanic American, Dr. Tansey has served as a role model to numerous undergraduate, graduate and post-graduate trainees, many of them women from under-represented groups in STEM. She served as Co-Director of Emory’s R25 Initiative for Maximizing Student Development (IMSD) whose mission is to strengthen institutional efforts to enhance recruitment and retention of diverse student and faculty bodies at Emory, by providing research training and mentoring opportunities to both. Dr. Tansey is a fierce advocate for women and other under-represented groups in STEM and has earned several mentoring awards from students and faculty for her efforts in this area.

In her spare time, Malú enjoys talking to patient and research-advocacy groups, cooking, sailing, and scuba-diving.

Additional Positions:
Editor-in-Chief
2021 – Current · Nature Portfolio Parkinson's Disease

Teaching Profile

Courses Taught
2019-2020,2022-2023
GMS6757 Introduction to Alzheimer’s Disease and Related Dementias: Clinical and Mechanistic Principles
2019
GMS7794 Neuroscience Seminar
2021-2023
GMS6029 Brain Journal Club
2022-2024
GMS6905 Independent Studies in Medical Sciences
2022-2024
GMS7980 Research for Doctoral Dissertation
2022-2024
GMS7979 Advanced Research
2023
GMS6090 Research in Medical Sciences
2024
GMS6971 Research for Master’s Thesis
2024
GMS7877 Responsible Conduct of Biomedical Research
Teaching Philosophy
I have been extremely fortunate to have outstanding mentors who were passionate about their day jobs, who were generous with their time, and who challenged me to stretch beyond my comfort zone. They always reminded me that if you’re not having fun playing detective you’re in the wrong business. They reminded me to not look over my shoulder at the competition, but rather do the best experiment I could do and to never propose anything I didn’t want to do. They told me “take care of the science, and the science will take care of you”. These have been words to live by that I share with my trainees. From these mentors I have learned about work-life integration and the importance of managing stress and relationships in the workplace. It was through the Emory’s Broadening Experiences in Scientific Training (BEST) program and my participation in a workshop as the mentor of a pre-doctoral trainee that I learned how powerful the Birkman Method could be to help me achieve this. After learning what my leadership style is and what my stress responses are when my needs aren’t met in the work place, I became convinced that knowing this information for ALL of my trainees would indeed help me become a better mentor and more importantly, would help us become a better research team. For this reason, I personally invested in my trainees and technicians and asked them to take the online assessment to promote self-awareness and more transparency with regards to areas of strengths in the 11 competencies evaluated in the Birkman. We then reviewed and discussed the outcome at our lab retreat in the North Georgia mountains with the short-term goal of learning how to form more effective and productive collaborations within the lab to advance our entire research mission. As an educator, my goal has been to light a fire that can ignite a love for learning rather than fill their bucket with knowledge. I believe that in the 21st century, as educators we should strive to help students to learn and adapt to change by becoming resourceful problem solvers. Given the vast amount of information that can now be streamed, learning is more about how to best connect the dots than about how to store information in one’s head. It’s important to meet students in their comfort zone to help them build confidence in themselves and trust in us as mentors; from there, they can stretch and take risks to discover new knowledge about the world and themselves. I have mentored multiple post-graduate, graduate, undergraduate, and high school students many of whom are now successful academic scientists, educators, career counselors, or scientific writers.

Research Profile

The research interests of our laboratory include investigating the role and regulation of immune and inflammatory mechanisms that protect against or predispose and individual to develop neurodegenerative disorders. Genetic and environmental contributions to lysosomal dysfunction and alterations in lipid signaling that dysregulate neuroimmune activity and trigger neuroinflammation are a main focus of investigation; as is the role of the gut-brain axis and chronic peripheral inflammation in the pathogenesis and progression of neurodegeneration.

Areas of Interest
  • Alzheimer’s Disease
  • FTD
  • Gut Microbiome
  • Microglia
  • Neuroimmune interactions in Neurodegenerative diseases
  • Neuroinflammation
  • Parkinson’s disease
Open Researcher and Contributor ID (ORCID)

0000-0002-1719-4708

Publications

2024
Calcium influx into astrocytes plays a pivotal role in inflammation-driven behaviors
Cell Calcium. 117 [DOI] 10.1016/j.ceca.2023.102838.
2023
APOE and immunity: Research highlights
Alzheimer's & Dementia. 19(6):2677-2696 [DOI] 10.1002/alz.13020.
2023
ASO-mediated knockdown or kinase inhibition of G2019S-Lrrk2 modulates lysosomal tubule-associated antigen presentation in macrophages
Molecular Therapy – Nucleic Acids. 34 [DOI] 10.1016/j.omtn.2023.102064. [PMID] 38028198.
2023
Central and peripheral innate and adaptive immunity in Parkinson’s disease
Science Translational Medicine. 15(721) [DOI] 10.1126/scitranslmed.adk3225.
2023
Editorial: Glial-targeted therapeutics for CNS disease: getting there from here
Frontiers in Cellular Neuroscience. 17 [DOI] 10.3389/fncel.2023.1231648. [PMID] 37465212.
2023
The Alzheimer’s risk gene APOE modulates the gut–brain axis
Nature. 614(7949):629-630 [DOI] 10.1038/d41586-023-00261-4.
2023
The complex role of inflammation and gliotransmitters in Parkinson’s disease
Neurobiology of Disease. 176 [DOI] 10.1016/j.nbd.2022.105940. [PMID] 36470499.
2022
Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer’s Symposium
Alzheimer's & Dementia. [DOI] 10.1002/alz.12589.
2022
Bacterial Butyrate in Parkinson’s Disease Is Linked to Epigenetic Changes and Depressive Symptoms
Movement Disorders. 37(8):1644-1653 [DOI] 10.1002/mds.29128. [PMID] 35723531.
2022
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis
Molecular Neurodegeneration. 17(1) [DOI] 10.1186/s13024-022-00515-1. [PMID] 35073950.
2022
Inflammation and immune dysfunction in Parkinson disease
Nature Reviews Immunology. [DOI] https://doi.org/10.1038/ s41577-022-00684-6.
2022
Inflammation and immune dysfunction in Parkinson disease
Nature Reviews Immunology. 22(11):657-673 [DOI] 10.1038/s41577-022-00684-6. [PMID] 35246670.
2022
Pathogenic tau recruits wild-type tau into brain inclusions and induces gut degeneration in transgenic SPAM mice
Communications Biology. 5(1) [DOI] 10.1038/s42003-022-03373-1. [PMID] 35550593.
2022
Profiles of women in science: Malú Gámez Tansey, Norman and Susan Fixel Professor of Neuroscience and Neurology, Co‐Director of the Center for Translational Research in Neurodegenerative Disease and Director of the Parkinson’s Foundation Research Center of Excellence, University of Florida College of Medicine
European Journal of Neuroscience. 55(2):350-353 [DOI] 10.1111/ejn.15578.
2021
Adolescent stress sensitizes the adult neuroimmune transcriptome and leads to sex-specific microglial and behavioral phenotypes
Neuropsychopharmacology. 46(5):949-958 [DOI] 10.1038/s41386-021-00970-2. [PMID] 33558677.
2021
Alzheimer’s disease research progress in Australia: The Alzheimer’s Association International Conference Satellite Symposium in Sydney
Alzheimer's & Dementia. [DOI] 10.1002/alz.12380.
2021
Author Correction: TNFα increases tyrosine hydroxylase expression in human monocytes
npj Parkinson's Disease. 7(1) [DOI] 10.1038/s41531-021-00212-8. [PMID] 34341346.
2021
Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology
Acta Neuropathologica Communications. 9(1) [DOI] 10.1186/s40478-021-01240-4. [PMID] 34412704.
2021
Genetic and Environmental Factors in P arkinson’s Disease Converge on Immune Function and Inflammation
Movement Disorders. 36(1):25-36 [DOI] 10.1002/mds.28411. [PMID] 33314312.
2021
Gut microbiome differences between amyotrophic lateral sclerosis patients and spouse controls
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 1-9 [DOI] 10.1080/21678421.2021.1904994.
2021
Inflammation-Related Factors Identified as Biomarkers of Dehydration and Subsequent Acute Kidney Injury in Agricultural Workers
Biological Research For Nursing. [DOI] 10.1177/10998004211016070. [PMID] 34018403.
2021
Is LRRK2 the missing link between inflammatory bowel disease and Parkinson’s disease?
npj Parkinson's Disease. 7(1) [DOI] 10.1038/s41531-021-00170-1. [PMID] 33750819.
2021
Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus
Nature Reviews Neurology. [DOI] 10.1038/s41582-021-00549-x. [PMID] 34522039.
2021
Poldip2 controls leukocyte infiltration into the ischemic brain by regulating focal adhesion kinase-mediated VCAM-1 induction
Scientific Reports. 11(1) [DOI] 10.1038/s41598-021-84987-z. [PMID] 33692398.
2021
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease
Molecular Neurodegeneration. 16(1) [DOI] 10.1186/s13024-021-00427-6. [PMID] 33557896.
2021
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease
Molecular Neurodegeneration. [DOI] https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-021-00427-6.
2021
TNFα increases tyrosine hydroxylase expression in human monocytes
npj Parkinson's Disease. 7(1) [DOI] 10.1038/s41531-021-00201-x. [PMID] 34285243.
2020
Alternatives to amyloid for Alzheimer’s disease therapies—a symposium report
Annals of the New York Academy of Sciences. 1475(1):3-14 [DOI] 10.1111/nyas.14371.
2020
Characterization of a Cul9–Parkin double knockout mouse model for Parkinson’s disease
Scientific Reports. 10(1) [DOI] 10.1038/s41598-020-73854-y. [PMID] 33037272.
2020
Chimeric Peptide Species Contribute to Divergent Dipeptide Repeat Pathology in c9ALS/FTD and SCA36
Neuron. 107(2):292-305.e6 [DOI] 10.1016/j.neuron.2020.04.011. [PMID] 32375063.
2020
Editorial for Special issue on Microbiome in neurological and psychiatric disease
Neurobiology of Disease. 135 [DOI] 10.1016/j.nbd.2019.104699.
2020
Linking mitochondria to the immune response
eLife. 9 [DOI] 10.7554/elife.56214.
2020
LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson’s
Frontiers in Neuroscience. 14 [DOI] 10.3389/fnins.2020.00443. [PMID] 32508566.
2020
Lysosome and Inflammatory Defects in GBA1 ‐Mutant Astrocytes Are Normalized by LRRK2 Inhibition
Movement Disorders. 35(5):760-773 [DOI] 10.1002/mds.27994. [PMID] 32034799.
2020
Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson’s disease: A case series
Neurobiology of Disease. 144 [DOI] 10.1016/j.nbd.2020.105027. [PMID] 32712266.
2020
Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson’s Disease
Molecules. 25(3) [DOI] 10.3390/molecules25030453. [PMID] 31973235.
2020
Molecular Signatures of Neuroinflammation Induced by αSynuclein Aggregates in Microglial Cells
Frontiers in Immunology. 11 [DOI] 10.3389/fimmu.2020.00033. [PMID] 32082315.
2020
Sexually dimorphic responses to MPTP found in microglia, inflammation and gut microbiota in a progressive monkey model of Parkinson’s disease
BioRxiV. [DOI] https://doi.org/10.1101/2020.01.30.925883.
2020
The gut microbiome and neuroinflammation in amyotrophic lateral sclerosis? Emerging clinical evidence
Neurobiology of Disease. 135 [DOI] 10.1016/j.nbd.2018.10.007.
2020
Transgenic mice expressing human alpha-synuclein in noradrenergic neurons develop locus coeruleus pathology and non-motor features of Parkinson’s disease
Journal of Neuroscience. [DOI] 10.1523/JNEUROSCI.1468-19.2020. .
2020
Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson’s Disease
The Journal of Neuroscience. 40(39):7559-7576 [DOI] 10.1523/jneurosci.1468-19.2020.
2020
What does plasma CRP tell us about peripheral and central inflammation in depression?
Molecular Psychiatry. 25(6):1301-1311 [DOI] 10.1038/s41380-018-0096-3. [PMID] 29895893.
2019
Chronic adolescent stress sex-specifically alters central and peripheral neuro-immune reactivity in rats
Brain, Behavior, and Immunity. 76:248-257 [DOI] 10.1016/j.bbi.2018.12.005. [PMID] 30550932.
2019
Chronic psychological stress during adolescence induces sex-dependent adulthood inflammation, increased adiposity, and abnormal behaviors that are ameliorated by selective inhibition of soluble tumor necrosis factor with XPro1595
Brain, Behavior, and Immunity. 81:305-316 [DOI] 10.1016/j.bbi.2019.06.027. [PMID] 31251975.
2019
Infection triggers symptoms similar to those of Parkinson’s disease in mice lacking PINK1 protein
Nature. 571(7766):481-482 [DOI] 10.1038/d41586-019-02094-6.
2019
LRRK2 regulation of immune-pathways and inflammatory disease
Biochemical Society Transactions. 47(6):1581-1595 [DOI] 10.1042/bst20180463.
2019
Spinal motor circuit synaptic plasticity after peripheral nerve injury depends on microglia activation and a CCR2 mechanism
The Journal of Neuroscience. 2945-17 [DOI] 10.1523/jneurosci.2945-17.2019.
2019
Targeting soluble tumor necrosis factor as a potential intervention to lower risk for late-onset Alzheimer’s disease associated with obesity, metabolic syndrome, and type 2 diabetes.
Alzheimer's research & therapy. 12(1) [DOI] 10.1186/s13195-019-0546-4. [PMID] 31892368.
2019
The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss
Experimental Neurology. 318:157-164 [DOI] 10.1016/j.expneurol.2019.05.002. [PMID] 31077715.
2018
An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 19(3-4):242-249 [DOI] 10.1080/21678421.2017.1421666.
2018
Challenges in Passive Immunization Strategies to Treat Parkinson Disease
JAMA Neurology. 75(10) [DOI] 10.1001/jamaneurol.2018.0346.
2018
Immune system responses in Parkinson’s disease: Early and dynamic
European Journal of Neuroscience. [DOI] 10.1111/ejn.14290. [PMID] 30474172.
2018
Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
Journal of Neuroinflammation. 15(1) [DOI] 10.1186/s12974-018-1171-z. [PMID] 29716614.
2018
Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson’s Disease
Movement Disorders. 33(5):793-804 [DOI] 10.1002/mds.27326. [PMID] 29572994.
2018
α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson’s Disease Pathogenesis
Frontiers in Neuroscience. 12 [DOI] 10.3389/fnins.2018.00626. [PMID] 30258347.
2017
A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation
Journal of Neuroinflammation. 14(1) [DOI] 10.1186/s12974-017-0906-6. [PMID] 28651603.
2017
Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease
Journal of Neuroinflammation. 14(1) [DOI] 10.1186/s12974-017-0935-1. [PMID] 28821274.
2017
Chronic psychological stress and high-fat high-fructose diet disrupt metabolic and inflammatory gene networks in the brain, liver, and gut and promote behavioral deficits in mice
Brain, Behavior, and Immunity. 59:158-172 [DOI] 10.1016/j.bbi.2016.08.021. [PMID] 27592562.
2017
LRRK2 levels in immune cells are increased in Parkinson’s disease
npj Parkinson's Disease. 3(1) [DOI] 10.1038/s41531-017-0010-8. [PMID] 28649611.
2017
Microglial phenotypes in Parkinson’s disease and animal models of the disease
Progress in Neurobiology. 155:57-75 [DOI] 10.1016/j.pneurobio.2016.04.006. [PMID] 27107797.
2017
Parkinsonism without dopamine neuron degeneration in agedl-dopa-responsive dystonia knockin mice
Movement Disorders. 32(12):1694-1700 [DOI] 10.1002/mds.27169. [PMID] 28949038.
2017
Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice
Neurobiology of Disease. 102:81-95 [DOI] 10.1016/j.nbd.2017.02.010. [PMID] 28237313.
2017
Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer’s (HEART) Trial
Journal of Alzheimer's Disease. 61(2):815-824 [DOI] 10.3233/jad-161198.
2017
The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?
npj Parkinson's Disease. 3(1) [DOI] 10.1038/s41531-016-0002-0. [PMID] 28649603.
2017
Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia
JCI Insight. 2(8) [DOI] 10.1172/jci.insight.87455. [PMID] 28422748.
2017
Toll-like Receptor 4 Mediates Morphine-Induced Neuroinflammation and Tolerance via Soluble Tumor Necrosis Factor Signaling
Neuropsychopharmacology. 42(3):661-670 [DOI] 10.1038/npp.2016.131. [PMID] 27461080.
2015
Common genetic variant association with altered HLA expression, synergy with pyrethroid exposure, and risk for Parkinson’s disease: an observational and case–control study
npj Parkinson's Disease. 1(1) [DOI] 10.1038/npjparkd.2015.2. [PMID] 27148593.
2014
Peripheral Administration of the Selective Inhibitor of Soluble Tumor Necrosis Factor (TNF) XPro®1595 Attenuates Nigral Cell Loss and Glial Activation in 6-OHDA Hemiparkinsonian Rats
Journal of Parkinson's Disease. 4(3):349-360 [DOI] 10.3233/jpd-140410.
2013
Progranulin Does Not Bind Tumor Necrosis Factor (TNF) Receptors and Is Not a Direct Regulator of TNF-Dependent Signaling or Bioactivity in Immune or Neuronal Cells
Journal of Neuroscience. 33(21):9202-9213 [DOI] 10.1523/jneurosci.5336-12.2013.
2013
Tumor Necrosis Factor–Neuropeptide Y Cross Talk Regulates Inflammation, Epithelial Barrier Functions, and Colonic Motility
Inflammatory Bowel Diseases. 19(12):2535-2546 [DOI] 10.1097/01.mib.0000437042.59208.9f.
2012
Ceramide sphingolipid signaling mediates Tumor Necrosis Factor (TNF)-dependent toxicity via caspase signaling in dopaminergic neurons
Molecular Neurodegeneration. 7(1) [DOI] 10.1186/1750-1326-7-45. [PMID] 22973882.
2011
Delayed Dominant-Negative TNF Gene Therapy Halts Progressive Loss of Nigral Dopaminergic Neurons in a Rat Model of Parkinson’s Disease
Molecular Therapy. 19(1):46-52 [DOI] 10.1038/mt.2010.217. [PMID] 20959812.
2009
Inhibition of soluble TNF signaling in a mouse model of Alzheimer’s disease prevents pre-plaque amyloid-associated neuropathology
Neurobiology of Disease. 34(1):163-177 [DOI] 10.1016/j.nbd.2009.01.006.
2008
Regulator of G-Protein Signaling 10 Promotes Dopaminergic Neuron Survival via Regulation of the Microglial Inflammatory Response
Journal of Neuroscience. 28(34):8517-8528 [DOI] 10.1523/jneurosci.1806-08.2008.
2006
Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson’s Disease
Journal of Neuroscience. 26(37):9365-9375 [DOI] 10.1523/jneurosci.1504-06.2006.
2003
Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants
Science. 301(5641):1895-1898 [DOI] 10.1126/science.1081297.
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease
Molecular Neurodegeneration. [DOI] 10.21203/rs.3.rs-63018/v1.
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease
Molecular Neurodegeneration. 16(6) [DOI] 10.21203/rs.3.rs-63018/v2.

Grants

Aug 2024 ACTIVE
Investigating the effects of LRRK2 mutations in immune exhuastion
Role: Other
Funding: PARKINSONS FOU
Aug 2024 ACTIVE
Small molecule anti-inflammatory studies in peripheral immune cells
Role: Principal Investigator
Funding: FORWARD THERAPEUTICS
Jun 2024 ACTIVE
Protective activity of XPro1595 against innate immune dysfunction ex vivo -INmune Bio Research Services Agreement
Role: Principal Investigator
Funding: INmune Bio, Inc.
Jan 2024 ACTIVE
Weston Family Foundation 2024
Role: Principal Investigator
Funding: WESTON FAMILY FOUNDATION
Nov 2023 ACTIVE
Investigation of disease- and pathogen-specific immune dysfunction traits in human PBMCs
Role: Principal Investigator
Funding: FOX FOU, MICHAEL J
Jan 2023 – Dec 2023
Weston Family Foundation FY23-24
Role: Principal Investigator
Funding: WESTON FAMILY FOUNDATION
Sep 2022 – Aug 2023
Proteins, Pathway, and Pathophysiology in Parkinson's Disease: a Gordon Research Conference
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Sep 2022 ACTIVE
Tau spreading through the gut-brain axis in a fly model of AD
Role: Co-Investigator
Funding: ALZHEIMERS ASSO
Aug 2022 ACTIVE
Role of central and peripheral immune crosstalk in FTD-Grn neurodegeneration
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Apr 2022 ACTIVE
The role of cannabinoid receptor 2 in the clearance of Tau by microglia
Role: Co-Investigator
Funding: ALZHEIMERS ASSO
Apr 2022 – Dec 2022
Weston Family Foundation FY23
Role: Principal Investigator
Funding: WESTON FAMILY FOUNDATION
Nov 2021 ACTIVE
Role of enteroendocrine cells in the origin of Parkinson's pathology
Role: Principal Investigator
Funding: DUKE UNIVERSITY via FOX FOU, MICHAEL J
Oct 2021 – Jul 2022
URMC-099 in in vivo AAV-hSYN and in vitro Dopaminergic Neuron Models
Role: Principal Investigator
Funding: FOX FOU, MICHAEL J
Jul 2021 – Dec 2023
The role of the peripheral immune-system in FTD-GRN; increasing understanding for future therapeutic target development
Role: Other
Funding: BRIGHTFOCUS FOU
Apr 2021 – Apr 2022
Weston Brain Institute Advisor Award 2021
Role: Principal Investigator
Funding: WESTON FAMILY FOUNDATION
Feb 2021 ACTIVE
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Dec 2020 – Mar 2024
The role of viral infection in immune dysregulation of innate and adaptive immune cells in the prodromal and clinical stages of Parkinsons disease.
Role: Principal Investigator
Funding: FOX FOU, MICHAEL J
Sep 2020 – Dec 2023
Validate PFF a-syn induced inflammatory phenotype in mice.
Role: Principal Investigator
Funding: FOX FOU, MICHAEL J
Aug 2020 – Apr 2023
Assessing LRRK2, GCase and cytokines in cryopreserved monocytes
Role: Principal Investigator
Funding: FOX FOU, MICHAEL J
Jul 2020 – Jul 2021
Weston Brain Institute Grant 2020
Role: Principal Investigator
Funding: WESTON BRAIN INSTITUTE
Jul 2020 – Oct 2022
Targeting solTNF-dependent inflammation in ALS with XPro1595 (ALSA)
Role: Principal Investigator
Funding: INmune Bio, Inc. via AMYOTROPHIC LATERAL SCLEROSIS ASSOC
Jun 2020 – Aug 2022
Role of Gut Inflammation and Immunity on Proteostasis, Noradrenergic Degeneration and AD risk
Role: Principal Investigator
Funding: NATL INST OF HLTH NIA
May 2020 – Apr 2022
Development of novel viral vectors to study and treat neuroinflammation
Role: Principal Investigator
Funding: ST JOSEPHS HOSPITAL AND MEDICAL CNTR via NATL INST OF HLTH NIA
Feb 2020 – Sep 2023
The role of cannabinoid receptor 2 in inflammatory responses triggered by alpha-synuclein
Role: Co-Project Director/Principal Investigator
Funding: FOX FOU, MICHAEL J
Dec 2019 – May 2024
LRRK2-Synuclein Interactions with Gut Inflammation in PD Pathogenesis
Role: Principal Investigator
Funding: PARKINSONS FOU
Nov 2019 – Nov 2020
Weston Brain Institute Grant 2019
Role: Principal Investigator
Funding: WESTON BRAIN INSTITUTE
Oct 2019 – Oct 2020
Weston Brain Institute Grant
Role: Principal Investigator
Funding: WESTON BRAIN INSTITUTE
Oct 2019 – Jul 2024
Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3
Role: Principal Investigator
Funding: NORTHWESTERN UNIV via NATL INST OF HLTH NINDS
Jul 2019 – Aug 2021
Targeting LRRK2 in models of GI inflammation
Role: Principal Investigator
Funding: FOX FOU, MICHAEL J
May 2017 – Jun 2020
Role of HLA/MHCII in Parkinson's Disease Pathogenesis
Role: Project Manager
Funding: EMORY UNIV via NATL INST OF HLTH NINDS

Contact Details

Phones:
Business:
(352) 294-4096
Emails:
Business:
mgtansey@ufl.edu
Addresses:
Business Mailing:
MCKNIGHT BRAIN INSTITUTE BLDG. LG-152
PO BOX 100244
8989 SW 75TH LANE
GAINESVILLE GA 326100244